12:00 AM
 | 
Feb 11, 2008
 |  BioCentury  |  Product Development

ACCORD design

ACCORD design

ACCORD design
Last week, the National Heart, Lung, and Blood Institute (NHLBI) discontinued the intensive glycemic arm (target HbA1c of <6%) of the ACCORD trial to prevent cardiovascular events in Type II...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >